We’re excited to announce that Biocytogen will attend the 19th IUIS Congress from August 17 to 22 in Vienna, Austria. Join us at this global gathering of immunology experts to explore our innovative antibody discovery platforms, humanized mouse models, and cutting-edge immuno-oncology research. Come meet our team and discover how we’re advancing the future of immunotherapy!
What is International Congress of Immunology (IUIS)?
The International Congress of Immunology (IUIS) is a prestigious global event held every three years by the International Union of Immunological Societies. It brings together thousands of scientists, clinicians, and industry leaders to share the latest advancements in immunology. The congress features cutting-edge research presentations, scientific sessions, and an international exhibition, making it a key platform for collaboration, innovation, and the advancement of immunological science and global health.
Event Overview
Date: August 17, 2025 - August 22, 2025
Venue: Austria Center Vienna (ACV), Bruno-Kreisky-Platz 1, 1220 Wien, Austria
Event Schedule
The International Congress of Immunology (IUIS) will feature world-renowned speakers, cutting-edge symposia, and an international exhibition showcasing the latest innovations in immunology. For the full event schedule please refer to IUIS.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to meeting you at the 19th International Congress of Immunology (IUIS) in Vienna, Austria.
